Cite
HARVARD Citation
Narayan, R. et al. (2020). A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia. Cancer. 126 (6), pp. 1264-1273. [Online].